表紙
市場調査レポート

関節炎:パイプライン製品の分析

Arthritis - Pipeline Review, H2 2014

発行 Global Markets Direct 商品コード 229756
出版日 ページ情報 英文 154 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.95円で換算しております。
Back to Top
関節炎:パイプライン製品の分析 Arthritis - Pipeline Review, H2 2014
出版日: 2014年07月31日 ページ情報: 英文 154 Pages
概要

関節炎とは、人体各所の関節の炎症を指します。関節の痛みや硬直化(特に午前中)が、関節の腫れと共に、典型的な徴候として挙げられています。また、関節の可動域が狭まる、関節周辺の皮膚が赤くなるといった症状も生じます。

当レポートでは、世界各国での関節炎治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

目次

イントロダクション

  • 分析範囲

関節炎の概要

治療薬の開発

  • 関節炎向けパイプライン製品:概要
  • 関節炎向けパイプライン製品:比較分析

各企業で開発中の関節炎治療薬

大学/研究機関で研究中の関節炎治療薬

パイプライン製品の概略

  • 治験段階の製品
  • 初期段階の製品
  • 不明確な段階にある製品

関節炎治療薬:開発中の製品の一覧(企業別)

関節炎治療薬:研究中の製品の一覧(大学/研究機関別)

関節炎治療薬の開発に従事している企業

  • Bristol-Myers Squibb Company
  • AstraZeneca PLC
  • GlaxoSmithKline plc
  • 大正製薬Taisho Pharmaceutical Co., Ltd.
  • Sylentis S.A.
  • アステラス製薬
  • エーザイ
  • Elan Corporation, plc
  • Teva Pharmaceutical Industries Limited
  • TheraKine Ltd.
  • Bone Medical Limited
  • Can-Fite BioPharma Ltd.
  • MEI Pharma, Inc.
  • Lexicon Pharmaceuticals, Inc.
  • CSL Limited
  • WhanIn Pharmaceutical Co., Ltd.
  • Oscotec Inc.
  • Viron Therapeutics, Inc.
  • PLx Pharma Inc.
  • Endocyte, Inc.
  • Taiwan Liposome Company, Ltd.
  • NasVax Ltd.
  • Georgia Tech Research Corporation
  • CalciMedica, Inc.
  • Zyngenia, Inc.
  • SelectX Pharmaceuticals, Inc.
  • AngioLab, Inc.
  • DoNatur GmbH
  • PharmaIN Corporation
  • CellAct Pharma GmbH
  • LegoChem Biosciences, Inc
  • Ampio Pharmaceuticals, Inc.
  • Inbiopro Solutions Pvt. Ltd.
  • Sagene Pharmaceuticals, Inc.
  • AnaMar AB
  • vida therapeutics inc.
  • Aurinia Pharmaceuticals Inc.
  • Dong-A Socio Holdings Co Ltd

関節炎:治療薬の評価

  • 単剤治療薬の場合
  • 併用治療薬の場合
  • 標的別
  • 作用機序別
  • 投与方法別
  • 分子の種類別

薬剤のプロファイル

  • ラキニモドナトリウム
    • 製品概要
    • 機能メカニズム
    • 研究開発(R&D)の進展状況
  • PL-1100
  • MCS-18
  • GLPG-0555
  • CSL-324
  • VT-346
  • CF-602
  • PL-5100
  • EC-1496
  • AMAP-102
  • DIS-BIO-OA01
  • 抗CD3経口免疫療法
  • BN-005
  • BN-008
  • Ampion
  • PGC-VIP
  • セレギリン+非ステロイド性抗炎症薬(NSAID)
  • AS-1940477
  • 酢酸デキサメタゾン
  • MDC-917
  • メタロプロテイナーゼ阻害薬
  • CAP-2.1
  • CAP-2.2
  • CAP1.1
  • PWT-143
  • AR-C-102222
  • 腫瘍壊死因子受容体:ハイブリッドFc領域
  • 中枢神経系(CNS)・筋骨格・呼吸器・代謝異常向けC-Rel阻害用小分子
  • 細胞間IL-1受容体拮抗薬
  • ペグ化アルギニンデイミナーゼ
  • スフィンゴシン-1-リン酸塩作動薬
  • DCB-3503
  • AT-132
  • ペプチジル・アリル・スルホン
  • TASP-0415914
  • プロピオン酸フルチカゾン
  • 二重特異性・抗-TNFalpha/Ang2 Zybody
  • 20(OH)D3
  • CIIF-4
  • OA-1
  • VLA-4拮抗薬
  • 間葉系幹細胞
  • TLC-599
  • GB-88
  • 関節炎・接触過敏症向けCCL20阻害用モノクローナル抗体
  • S100-A8
  • CM-3457
  • 関節炎向け医薬品
  • SYK阻害薬
  • ADAMTS-5阻害薬
  • WIP-901C
  • 非免疫抑制的シクロスポリン・アナログ(類似体)分子プログラム
  • 心血管疾患・筋骨格障害・腫瘍・免疫疾患向けマトリックスメタロプロテアーゼ阻害剤
  • Gタンパク質共役受容体の特定サブタイプ標的薬
  • OPK-30020
  • 慢性炎症疾患向け医薬品
  • OPK-13031
  • フィブリン阻害ペプチド
  • ペプチド阻害薬
  • EMMPRIN抱合体
  • BMP-2モジュレーター
  • CD-99阻害剤
  • 第IV因子ベースsiRNA
  • IBPB-001-PH

関節炎治療薬:パイプライン製品の最新動向

関節炎治療薬:開発が休止状態の製品

関節炎治療薬:開発が中止された製品

関節炎関連製品の開発のマイルストーン

  • 注目すべき最新動向・プレスリリース(全10件)

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC5196IDB

Summary

Global Markets Direct's, 'Arthritis - Pipeline Review, H2 2014', provides an overview of the Arthritis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Arthritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Arthritis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Arthritis
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Arthritis and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Arthritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Arthritis pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Arthritis
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Arthritis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Arthritis Overview
  • Therapeutics Development
    • Pipeline Products for Arthritis - Overview
    • Pipeline Products for Arthritis - Comparative Analysis
  • Arthritis - Therapeutics under Development by Companies
  • Arthritis - Therapeutics under Investigation by Universities/Institutes
  • Arthritis - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Arthritis - Products under Development by Companies
  • Arthritis - Products under Investigation by Universities/Institutes
  • Arthritis - Companies Involved in Therapeutics Development
    • Eli Lilly and Company
    • GlaxoSmithKline plc
    • Nemucore Medical Innovations, Inc.
    • Taisho Pharmaceutical Co., Ltd.
    • Sylentis S.A.
    • Astellas Pharma Inc.
    • Eisai Co., Ltd.
    • Bone Medical Limited
    • Momenta Pharmaceuticals, Inc.
    • Can-Fite BioPharma Ltd.
    • Lexicon Pharmaceuticals, Inc.
    • CSL Limited
    • WhanIn Pharmaceutical Co., Ltd.
    • Oscotec Inc.
    • Viron Therapeutics, Inc.
    • PLx Pharma Inc.
    • Endocyte, Inc.
    • Cardax Pharmaceuticals, Inc.
    • Taiwan Liposome Company, Ltd.
    • NasVax Ltd.
    • CalciMedica, Inc.
    • Zyngenia, Inc.
    • SelectX Pharmaceuticals, Inc.
    • DoNatur GmbH
    • CellAct Pharma GmbH
    • Arcarios BV
    • Inbiopro Solutions Pvt. Ltd.
    • Sagene Pharmaceuticals, Inc.
    • vida therapeutics inc.
    • Dong-A Socio Group
  • Arthritis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • vancomycin hydrochloride - Drug Profile
    • PL-1100 - Drug Profile
    • MCS-18 - Drug Profile
    • GLPG-0555 - Drug Profile
    • LY-3114062 - Drug Profile
    • CSL-324 - Drug Profile
    • VT-346 - Drug Profile
    • CF-602 - Drug Profile
    • CDX-085 - Drug Profile
    • PL-5100 - Drug Profile
    • EC-1496 - Drug Profile
    • AMAP-102 - Drug Profile
    • ABC-294640 - Drug Profile
    • Anti-CD3 Oral Immunotherapy - Drug Profile
    • IBPB-001PH - Drug Profile
    • selegiline + NSAIDs - Drug Profile
    • AS-1940477 - Drug Profile
    • dexamethasone acetate - Drug Profile
    • MDC-917 - Drug Profile
    • Small Molecules to Inhibit MMP - Drug Profile
    • CAP-2.1 - Drug Profile
    • CAP-2.2 - Drug Profile
    • CAP1.1 - Drug Profile
    • Recombinant Protein to Inhibit TNF-Alpha for Inflammatory Diseases - Drug Profile
    • Small Molecules to Inhibit C-Rel for Central Nervous System, Musculoskeletal, Respiratory and Metabolic Disorders - Drug Profile
    • OXT-328 - Drug Profile
    • Peptide to Inhibit Intracellular IL-1 Receptor for Musculoskeletal, Dermatology and Central Nervous System Disorders - Drug Profile
    • Peptides to Inhibit MHC Class I and II for CNS Disorders and Musculoskeletal - Drug Profile
    • Antibody for Autoimmune Disorders and Inflammation - Drug Profile
    • DCB-3503 - Drug Profile
    • AT-132 - Drug Profile
    • TASP-0415914 - Drug Profile
    • fluticasone propionate - Drug Profile
    • Monoclonal Antibody to Inhibit Ang-2 and TNF-a - Drug Profile
    • CIIF-4 - Drug Profile
    • OA-1 - Drug Profile
    • TLC-599 - Drug Profile
    • Monoclonal Antibody to Inhibit CCL20 for Arthritis and Contact Hypersensitivity - Drug Profile
    • Small Molecule to Activate S100A8 for Arthritis - Drug Profile
    • CM-3457 - Drug Profile
    • Drugs to Activate P58IPK for Arthritis - Drug Profile
    • IMSB-001 - Drug Profile
    • RNAi Oligonucleotide for Arthritis and Gastrointestinal Disorders - Drug Profile
    • BN-005 - Drug Profile
    • BN-008 - Drug Profile
    • Small Molecule to Inhibit SYK for Arthritis - Drug Profile
    • Small Molecule to Inhibit ADAMTS-5 for Arthritis - Drug Profile
    • WIP-901C - Drug Profile
    • Small Molecules to Inhibit Cyclophilins - Drug Profile
    • Drug for Chronic Inflammatory Diseases - Drug Profile
    • Peptides to Inhibit Fibrinogen and ICAM-1 for Oncology, Inflammtion, Arthritis, Cardiovascular Disease and Bleeding Disorders - Drug Profile
    • Peptides to Inhibit TNF-a for Immunology, Oncology and Musculoskeletal Disorders - Drug Profile
    • Small Molecules to Inhibit CD147 for Immunology, Oncology, Womens Health and Musculoskeletal Disorders - Drug Profile
    • Small Molecules to Modulate BMP-2 for Arthritis - Drug Profile
    • FIV-based siRNA - Drug Profile
    • Gene Therapy for Arthritis - Drug Profile
    • NMI-4100 - Drug Profile
  • Arthritis - Recent Pipeline Updates
  • Arthritis - Dormant Projects
  • Arthritis - Discontinued Products
  • Arthritis - Product Development Milestones
  • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Arthritis, H2 2014
  • Number of Products under Development for Arthritis - Comparative Analysis, H2 2014
  • Number of Products under Development by Companies, H2 2014
  • Number of Products under Development by Companies, H2 2014 (Contd..1)
  • Number of Products under Development by Companies, H2 2014 (Contd..2)
  • Number of Products under Investigation by Universities/Institutes, H2 2014
  • Comparative Analysis by Late Stage Development, H2 2014
  • Comparative Analysis by Clinical Stage Development, H2 2014
  • Comparative Analysis by Early Stage Development, H2 2014
  • Products under Development by Companies, H2 2014
  • Products under Development by Companies, H2 2014 (Contd..1)
  • Products under Investigation by Universities/Institutes, H2 2014
  • Arthritis - Pipeline by Eli Lilly and Company, H2 2014
  • Arthritis - Pipeline by GlaxoSmithKline plc, H2 2014
  • Arthritis - Pipeline by Nemucore Medical Innovations, Inc., H2 2014
  • Arthritis - Pipeline by Taisho Pharmaceutical Co., Ltd., H2 2014
  • Arthritis - Pipeline by Sylentis S.A., H2 2014
  • Arthritis - Pipeline by Astellas Pharma Inc., H2 2014
  • Arthritis - Pipeline by Eisai Co., Ltd., H2 2014
  • Arthritis - Pipeline by Bone Medical Limited, H2 2014
  • Arthritis - Pipeline by Momenta Pharmaceuticals, Inc., H2 2014
  • Arthritis - Pipeline by Can-Fite BioPharma Ltd., H2 2014
  • Arthritis - Pipeline by Lexicon Pharmaceuticals, Inc., H2 2014
  • Arthritis - Pipeline by CSL Limited, H2 2014
  • Arthritis - Pipeline by WhanIn Pharmaceutical Co., Ltd., H2 2014
  • Arthritis - Pipeline by Oscotec Inc., H2 2014
  • Arthritis - Pipeline by Viron Therapeutics, Inc., H2 2014
  • Arthritis - Pipeline by PLx Pharma Inc., H2 2014
  • Arthritis - Pipeline by Endocyte, Inc., H2 2014
  • Arthritis - Pipeline by Cardax Pharmaceuticals, Inc., H2 2014
  • Arthritis - Pipeline by Taiwan Liposome Company, Ltd., H2 2014
  • Arthritis - Pipeline by NasVax Ltd., H2 2014
  • Arthritis - Pipeline by CalciMedica, Inc., H2 2014
  • Arthritis - Pipeline by Zyngenia, Inc., H2 2014
  • Arthritis - Pipeline by SelectX Pharmaceuticals, Inc., H2 2014
  • Arthritis - Pipeline by DoNatur GmbH, H2 2014
  • Arthritis - Pipeline by CellAct Pharma GmbH, H2 2014
  • Arthritis - Pipeline by Arcarios BV, H2 2014
  • Arthritis - Pipeline by Inbiopro Solutions Pvt. Ltd., H2 2014
  • Arthritis - Pipeline by Sagene Pharmaceuticals, Inc., H2 2014
  • Arthritis - Pipeline by vida therapeutics inc., H2 2014
  • Arthritis - Pipeline by Dong-A Socio Group, H2 2014
  • Assessment by Monotherapy Products, H2 2014
  • Assessment by Combination Products, H2 2014
  • Number of Products by Stage and Target, H2 2014
  • Number of Products by Stage and Mechanism of Action, H2 2014
  • Number of Products by Stage and Route of Administration, H2 2014
  • Number of Products by Stage and Molecule Type, H2 2014
  • Arthritis Therapeutics - Recent Pipeline Updates, H2 2014
  • Arthritis - Dormant Projects, H2 2014
  • Arthritis - Discontinued Products, H2 2014

List of Figures

  • Number of Products under Development for Arthritis, H2 2014
  • Number of Products under Development for Arthritis - Comparative Analysis, H2 2014
  • Number of Products under Development by Companies, H2 2014
  • Number of Products under Investigation by Universities/Institutes, H2 2014
  • Comparative Analysis by Clinical Stage Development, H2 2014
  • Comparative Analysis by Early Stage Products, H2 2014
  • Assessment by Monotherapy Products, H2 2014
  • Number of Products by Top 10 Target, H2 2014
  • Number of Products by Stage and Top 10 Target, H2 2014
  • Number of Products by Top 10 Mechanism of Action, H2 2014
  • Number of Products by Stage and Top 10 Mechanism of Action, H2 2014
  • Number of Products by Top 10 Route of Administration, H2 2014
  • Number of Products by Stage and Top 10 Route of Administration, H2 2014
  • Number of Products by Top 10 Molecule Type, H2 2014
  • Number of Products by Stage and Top 10 Molecule Type, H2 2014
Back to Top